Program
4CMenB vaccine
Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.
In GlaxoSmithKline’s pipeline, Recombinant protein and outer membrance vesicle vaccine
. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 130 open or running | phase 3since Apr 2, 2008 | Feb 27, 2006 | none ahead |
| Pfizerits history only | 90 open or running | phase 4since May 14, 2021 | Oct 11, 2006 | none ahead |
| GlaxoSmithKlineits history only | 71 open or running | phase 4since Feb 6, 2018 | Feb 14, 2014 | none ahead |
| Sanofi | 20 open or running | phase 3since Sep 4, 2019 | Sep 4, 2019 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
Men B vaccine GSK3536829
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 4, 2019First study: phase 3 study in Meningococcal Immunisation (Healthy Volunteers)First studyNCT04084769 · 570 enrolled · United States, Puerto Rico
- Oct 26, 2023Phase 2 study in Meningococcal ImmunisationNCT06128733 · 1,215 enrolled · United States, Puerto Rico
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule
Studies
All 2 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06128733Meningococcal Immunisation · United States, Puerto Rico | 2 | Completed | Aug 27, 2025 | 1,215 |
| NCT04084769Meningococcal Immunisation (Healthy Volunteers) · United States, Puerto Rico | 3 | Completed | Sep 14, 2020 | 570 |
How it is read
Names in the registry
- “rLP2086”, 11 entries
- “rMenB+OMV NZ”, 9 entries
- “Meningococcal B vaccine”, 6 entries
- “rMenB+OMV NZ vaccine”, 3 entries
- “Meningococcal group B vaccine”, 3 entries
Conditions, from the studies’ own filings
- Meningococcal Infections, 10 studies
- Meningitis, Meningococcal, 9 studies
- Meningitis, 2 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.